PIK3CA mutations and BRCA1 expression in breast cancer: Potential biomarkers for chemoresistance

Mariacarmela Santarpia, Giuseppe Altavilla, Mireia Margeli, Beatriz Cirauqui, Mario Mesiti, Vittorio Cavallari, Jose Luis Ramirez, Maria Sanchez-Ronco, Libero Santarpia, Miquel Taron, Rafael Rosell

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Mutations in PIK3CA and alterations of BRCA1 expression are common in breast cancer and have been correlated with altered sensitivity to taxanes in human cancer cell lines and with outcome of patients. We assessed mutations in the three hotspots of PIK3CA (E542K, E545K and H1047R) and intratumoral BRCA1 mRNA expression by quantitative RT-PCR in 61 breast cancer patients. Mutations of PIK3CA were found in 17 (27.9%) and did not correlate with BRCA1 transcript levels. Correlation with clinical and pathological features identified a significant association of mutations with older patients (P = 0.03). Higher BRCA1 mRNA expression was significantly correlated with advanced disease (P = 0.01) and ERBB2 overexpression (P = 0.02). These findings may help to identify a subgroup of patients who will likely benefit from chemotherapy regimens containing microtubule-disrupting agents.

Original languageEnglish
Pages (from-to)1044-1051
Number of pages8
JournalCancer Investigation
Volume26
Issue number10
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Tumor Biomarkers
Breast Neoplasms
Mutation
Taxoids
Messenger RNA
Microtubules
Drug Therapy
Cell Line
Polymerase Chain Reaction
Neoplasms

Keywords

  • BRCA1 expression
  • Breast cancer
  • Chemoresistance
  • PIK3CA mutations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Santarpia, M., Altavilla, G., Margeli, M., Cirauqui, B., Mesiti, M., Cavallari, V., ... Rosell, R. (2008). PIK3CA mutations and BRCA1 expression in breast cancer: Potential biomarkers for chemoresistance. Cancer Investigation, 26(10), 1044-1051. https://doi.org/10.1080/07357900802112701

PIK3CA mutations and BRCA1 expression in breast cancer : Potential biomarkers for chemoresistance. / Santarpia, Mariacarmela; Altavilla, Giuseppe; Margeli, Mireia; Cirauqui, Beatriz; Mesiti, Mario; Cavallari, Vittorio; Ramirez, Jose Luis; Sanchez-Ronco, Maria; Santarpia, Libero; Taron, Miquel; Rosell, Rafael.

In: Cancer Investigation, Vol. 26, No. 10, 12.2008, p. 1044-1051.

Research output: Contribution to journalArticle

Santarpia, M, Altavilla, G, Margeli, M, Cirauqui, B, Mesiti, M, Cavallari, V, Ramirez, JL, Sanchez-Ronco, M, Santarpia, L, Taron, M & Rosell, R 2008, 'PIK3CA mutations and BRCA1 expression in breast cancer: Potential biomarkers for chemoresistance', Cancer Investigation, vol. 26, no. 10, pp. 1044-1051. https://doi.org/10.1080/07357900802112701
Santarpia M, Altavilla G, Margeli M, Cirauqui B, Mesiti M, Cavallari V et al. PIK3CA mutations and BRCA1 expression in breast cancer: Potential biomarkers for chemoresistance. Cancer Investigation. 2008 Dec;26(10):1044-1051. https://doi.org/10.1080/07357900802112701
Santarpia, Mariacarmela ; Altavilla, Giuseppe ; Margeli, Mireia ; Cirauqui, Beatriz ; Mesiti, Mario ; Cavallari, Vittorio ; Ramirez, Jose Luis ; Sanchez-Ronco, Maria ; Santarpia, Libero ; Taron, Miquel ; Rosell, Rafael. / PIK3CA mutations and BRCA1 expression in breast cancer : Potential biomarkers for chemoresistance. In: Cancer Investigation. 2008 ; Vol. 26, No. 10. pp. 1044-1051.
@article{d4cbe3f2f7684018a5ff6312d771149c,
title = "PIK3CA mutations and BRCA1 expression in breast cancer: Potential biomarkers for chemoresistance",
abstract = "Mutations in PIK3CA and alterations of BRCA1 expression are common in breast cancer and have been correlated with altered sensitivity to taxanes in human cancer cell lines and with outcome of patients. We assessed mutations in the three hotspots of PIK3CA (E542K, E545K and H1047R) and intratumoral BRCA1 mRNA expression by quantitative RT-PCR in 61 breast cancer patients. Mutations of PIK3CA were found in 17 (27.9{\%}) and did not correlate with BRCA1 transcript levels. Correlation with clinical and pathological features identified a significant association of mutations with older patients (P = 0.03). Higher BRCA1 mRNA expression was significantly correlated with advanced disease (P = 0.01) and ERBB2 overexpression (P = 0.02). These findings may help to identify a subgroup of patients who will likely benefit from chemotherapy regimens containing microtubule-disrupting agents.",
keywords = "BRCA1 expression, Breast cancer, Chemoresistance, PIK3CA mutations",
author = "Mariacarmela Santarpia and Giuseppe Altavilla and Mireia Margeli and Beatriz Cirauqui and Mario Mesiti and Vittorio Cavallari and Ramirez, {Jose Luis} and Maria Sanchez-Ronco and Libero Santarpia and Miquel Taron and Rafael Rosell",
year = "2008",
month = "12",
doi = "10.1080/07357900802112701",
language = "English",
volume = "26",
pages = "1044--1051",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - PIK3CA mutations and BRCA1 expression in breast cancer

T2 - Potential biomarkers for chemoresistance

AU - Santarpia, Mariacarmela

AU - Altavilla, Giuseppe

AU - Margeli, Mireia

AU - Cirauqui, Beatriz

AU - Mesiti, Mario

AU - Cavallari, Vittorio

AU - Ramirez, Jose Luis

AU - Sanchez-Ronco, Maria

AU - Santarpia, Libero

AU - Taron, Miquel

AU - Rosell, Rafael

PY - 2008/12

Y1 - 2008/12

N2 - Mutations in PIK3CA and alterations of BRCA1 expression are common in breast cancer and have been correlated with altered sensitivity to taxanes in human cancer cell lines and with outcome of patients. We assessed mutations in the three hotspots of PIK3CA (E542K, E545K and H1047R) and intratumoral BRCA1 mRNA expression by quantitative RT-PCR in 61 breast cancer patients. Mutations of PIK3CA were found in 17 (27.9%) and did not correlate with BRCA1 transcript levels. Correlation with clinical and pathological features identified a significant association of mutations with older patients (P = 0.03). Higher BRCA1 mRNA expression was significantly correlated with advanced disease (P = 0.01) and ERBB2 overexpression (P = 0.02). These findings may help to identify a subgroup of patients who will likely benefit from chemotherapy regimens containing microtubule-disrupting agents.

AB - Mutations in PIK3CA and alterations of BRCA1 expression are common in breast cancer and have been correlated with altered sensitivity to taxanes in human cancer cell lines and with outcome of patients. We assessed mutations in the three hotspots of PIK3CA (E542K, E545K and H1047R) and intratumoral BRCA1 mRNA expression by quantitative RT-PCR in 61 breast cancer patients. Mutations of PIK3CA were found in 17 (27.9%) and did not correlate with BRCA1 transcript levels. Correlation with clinical and pathological features identified a significant association of mutations with older patients (P = 0.03). Higher BRCA1 mRNA expression was significantly correlated with advanced disease (P = 0.01) and ERBB2 overexpression (P = 0.02). These findings may help to identify a subgroup of patients who will likely benefit from chemotherapy regimens containing microtubule-disrupting agents.

KW - BRCA1 expression

KW - Breast cancer

KW - Chemoresistance

KW - PIK3CA mutations

UR - http://www.scopus.com/inward/record.url?scp=57749201846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57749201846&partnerID=8YFLogxK

U2 - 10.1080/07357900802112701

DO - 10.1080/07357900802112701

M3 - Article

C2 - 18798071

AN - SCOPUS:57749201846

VL - 26

SP - 1044

EP - 1051

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 10

ER -